U.S. drug regulators, the FDA requested additional data on Novo Nordisk’s new long-acting insulin drug, Tresiba, in regards to potential heart risks. The drug-maker said that it could not provide the data for more than a year. To learn more about this click here…….
This site uses Akismet to reduce spam. Learn how your comment data is processed.